Ulcerative Colitis Treatment Lead To Progressive Multifocal Leukoencephlopathy
If you suffer from either ulcerative colitis or Crohn’s disease and your doctor wants to tell you about an experimental drug, called Entyvio, as a ulcerative colitis treatment option, think carefully before you give the go ahead. There are some things you should know first… and they’re things that your doctor may not even know about.
We’ve been here before…
Back in December, the American Food and Drug Administration (FDA) announced that it was very alarmed about the dangers of Entyvio. So much so that it wondered if its risks could possibly outweigh the benefits.The FDA considered restricting the use of Entyvio for Ulcerative Colitis Treatment and there was even talk about a black box warning… trial data showed that the drug didn’t succeed in putting patients in remission after 6 weeks of ulcerative colitis treatment and it carries the risk of “liver injury that may lead to death” or require a liver transplant, as well as allergic reactions and infections.However, as if by magic, all those concerns vanished by the end of May 2014 when the FDA made a 180 degree turn-around and approved this risky Crohn’s disease and ulcerative colitis treatment.The big worry is that Entyvio for Ulcerative Colitis Treatment works just like Tysabri – a multiple sclerosis drug that was pulled from the market in 2005 because it triggered a rare virus that attacks the brain.This deadly viral brain infection is called progressive multifocal leukoencephlopathy (PML) and back in 2005 the FDA put all Tysabri drug trials on hold when several patients came down with PML.